Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein vaccine for inhibiting clostridium perfringens infection

A technology for Clostridium perfringens and vaccines, which can be applied to fusion polypeptides, hybrid peptides, antibacterial drugs, etc., and can solve problems such as difficulty in increasing the renaturation rate.

Inactive Publication Date: 2016-10-12
CHINA ANIMAL DISEASE CONTROL CENT
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Protein denaturation and renaturation is an extremely complicated process. The renaturation conditions of different proteins are different, and the renaturation rate is often difficult to improve.
This is the main constraint limiting its application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein vaccine for inhibiting clostridium perfringens infection
  • Fusion protein vaccine for inhibiting clostridium perfringens infection
  • Fusion protein vaccine for inhibiting clostridium perfringens infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Example 1. Soluble expression of α-β2-ε-his

[0086] 1. Synthetic genes

[0087] The application designed three fusion genes, which are α-β2-ε-hisY gene shown in SEQ ID No.1, α-β2-ε-hisW gene shown in SEQ ID No.3, and SEQ ID No.4 The indicated pmα-β2-ε-hisW gene.

[0088] Both the α-β2-ε-hisY gene and the α-β2-ε-hisW gene encode the protein α-β2-ε-his shown in SEQ ID No.2. The pmα-β2-ε-hisW gene encodes the protein pmα-β2-ε-hisW shown in SEQ ID No.5. α-β2-ε-his is a protein obtained by deleting amino acid residues 52-146, 464-492 and 743-750 of pmα-β2-ε-hisW.

[0089] The α-β2-ε-Y gene shown in the 151-2814th position of SEQ ID No.1 is synthesized by chemical synthesis (the protein shown in the 51-937th amino acid residue of encoding SEQ ID No.2) , the α-β2-ε-W gene shown in the 151-2814th position of SEQ ID No.3 (the protein shown in the 51-937th amino acid residue of encoding SEQ ID No.2), SEQ ID No.4 The pmα-β2-ε-W gene shown at positions 151-3210 of the pmα-β2-...

Embodiment 2

[0110] Embodiment 2, animal immune protective test of α-β2-ε-his

[0111] 1. Preparation of anti-Clostridium perfringens vaccine

[0112] The α-β2-ε-his protein purified by molecular sieves in Example 1 was dissolved in sterile PBS to obtain an α-β2-ε-his solution with an α-β2-ε-his concentration of 1000 μg / mL for immunization. The α-β2-ε-his solution and Freund's adjuvant were mixed in an equal volume of 1:1, and emulsified to prepare an oil emulsion vaccine, which was named the first vaccine. The α-β2-ε-his solution and incomplete Freund's adjuvant were mixed in equal volumes of 1:1, and emulsified to prepare an oil emulsion vaccine, which was named as the secondary vaccine.

[0113] Take out the A-type Clostridium perfringens virulent strain C57-10, the B-type Clostridium perfringens virulent strain C58-5, and the C-type Clostridium perfringens virulent strain purchased from the China Veterinary Drug Administration. Strain C59-4, Clostridium perfringens type D virulent st...

Embodiment 3

[0136] Example 3, Optimization of α-β2-ε-his Induced Expression Conditions

[0137] 1. Optimization of induction temperature and time

[0138] Inoculate BL21(DE3) / pET30a-α-β2-ε-Y in LB liquid medium containing 50 μg / ml kanamycin (add kanamycin to LB liquid medium until the concentration of kanamycin is 50 μg / ml obtained medium), 37 ° C, using Thermo MaxQ6000 type full-temperature shaker 200 rpm shaking culture to OD 600 When the value (the LB liquid medium containing 50 μg / ml kanamycin was used as the blank control) reached 0.6, isopropylthio-β-D-galactoside (IPTG) was added to induce the following six kinds of expression respectively. The first induced expression was induced with 0.75 mM IPTG for 1 hour at 37°C. The second induced expression was induced with 0.75 mM IPTG for 2 hours at 37°C. The third induced expression was induced with 0.75 mM IPTG for 4 hours at 37°C. The fourth induced expression was induced with 0.75 mM IPTG for 5 hours at 37°C. The fifth induced exp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses a fusion protein vaccine for inhibiting clostridium perfringens infection. The vaccine contains protein shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.937 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or / and amino terminals of the protein shown in (a) or (b). The vaccine enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the vaccine. The immune protective rates of the vaccine within seven days when the vaccine resists the attack of clostridium perfringens type A, clostridium perfringens type B, clostridium perfringens type C and clostridium perfringens type D are 100%, 100%, 90% and 100% correspondingly, and the highest antibody valence is up to 1:128,000.

Description

technical field [0001] The invention relates to a fusion protein vaccine for inhibiting Clostridium perfringens infection in the field of biotechnology. Background technique [0002] Clostridium perfringens (Clostridium Perfringens), also known as Clostridium welchii, is an important zoonotic disease. The pathogen is traumatic gas gangrene and human food poisoning, as well as sheep blight, lamb dysentery, and necrosis of cattle and sheep. It is one of the main pathogens of acute enteritis and cattle and sheep enterotoxemia, which has caused huge economic losses to animal husbandry. The main pathogenic factor of Clostridium perfringens is the exotoxin secreted by it. There are as many as 13 types, among which α, β and ε are the most important exotoxins. According to the different types of exotoxins produced, the perfringens can be Clostridium mycobacterium is divided into five serotypes A, B, C, D, and E. At present, immunization against Clostridium perfringens is mainly ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/08C07K14/33C07K19/00C12N15/31C12N15/70A61P31/04
CPCA61K39/08C07K14/33C07K2319/00C07K2319/21C12N15/70C12N2800/101
Inventor 宋晓晖孙雨翟新验赵柏林
Owner CHINA ANIMAL DISEASE CONTROL CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com